Lilly(US:LLY) GLP1减重宝典·2025-11-20 14:44Core Viewpoint - The article discusses the recent developments regarding Eli Lilly's drug Tirzepatide, including its current status in the Chinese market and potential future approvals for additional indications [4][6]. Group 1: Drug Approval Status - On November 17, the National Medical Products Administration (NMPA) of China issued a notification regarding Eli Lilly's Tirzepatide injection, indicating that the application has not yet been approved but can still proceed with further data submission [4]. - The notification includes four application numbers: JXHS2400108, JXHS2400109, JXHS2400110, and JXHS2400111, with a date of issuance on November 14, 2025 [5]. Group 2: Current Indications - Tirzepatide has received approval in China for three indications: for adults with type 2 diabetes who have inadequate blood sugar control, for improving blood sugar control in adults with type 2 diabetes when used with insulin, and for long-term weight management in adults with obesity or overweight [6]. - Additionally, Tirzepatide is approved for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity [6]. Group 3: Speculated Future Indications - Industry insiders speculate that the application may be for the indication of "heart failure with preserved ejection fraction associated with obesity," which is still under registration approval in the United States [5].